For: | Sato K, Yamazaki Y, Ohyama T, Kobayashi T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World J Clin Cases 2016; 4(3): 88-93 [PMID: 26989674 DOI: 10.12998/wjcc.v4.i3.88] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v4/i3/88.htm |
Number | Citing Articles |
1 |
Tatsuya Ide, Yuichiro Eguchi, Masaru Harada, Kunihide Ishii, Masaru Morita, Yasuyo Morita, Gen Sugiyama, Hirofumi Fukushima, Yoichi Yano, Kazunori Noguchi, Hiroki Nakamura, Junjiro Hisatomi, Hiroto Kumemura, Miki Shirachi, Shinji Iwane, Michiaki Okada, Yuichi Honma, Teruko Arinaga-Hino, Ichiro Miyajima, Kei Ogata, Reiichiro Kuwahara, Keisuke Amano, Toshihiro Kawaguchi, Ryoko Kuromatsu, Takuji Torimura, Chen-Hua Liu. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLOS ONE 2016; 11(9): e0163884 doi: 10.1371/journal.pone.0163884
|
2 |
Ken Sato, Kenichi Hosonuma, Yuichi Yamazaki, Takeshi Kobayashi, Satoshi Takakusagi, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Hiroshi Ohnishi, Hiroaki Okamoto, Masanobu Yamada. Combination Therapy with Ombitasvir/Paritaprevir/Ritonavir for Dialysis Patients Infected with Hepatitis C Virus: A Prospective Multi-Institutional Study. The Tohoku Journal of Experimental Medicine 2017; 241(1): 45 doi: 10.1620/tjem.241.45
|
3 |
Lionel Rostaing, Laurent Alric, Nassim Kamar. Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. Transplant International 2016; 29(12): 1257 doi: 10.1111/tri.12870
|
4 |
Fabrizio Fabrizi, Francesca M. Donato, Piergiorgio Messa. Direct-acting Antivirals for Hepatitis C Virus in Patients on Maintenance Dialysis. The International Journal of Artificial Organs 2017; 40(10): 531 doi: 10.5301/ijao.5000613
|
5 |
Maurizio Salvadori, Aris Tsalouchos. Hepatitis C and renal transplantation in era of new antiviral agents. World Journal of Transplantation 2018; 8(4): 84-96 doi: 10.5500/wjt.v8.i4.84
|
6 |
Masanori Atsukawa, Chisa Kondo, Tadamichi Kawano, Tomomi Okubo, Taeang Arai, Ai Nakagawa-Iwashita, Norio Itokawa, Katsuhiko Iwakiri. Development of Interferon-Free, Direct-Acting Antivirals Treatment for Japanese Patients with Chronic Hepatitis C Infection and Chronic Kidney Disease. Journal of Nippon Medical School 2021; 88(3): 163 doi: 10.1272/jnms.JNMS.2021_88-316
|
7 |
He-chuan Wang, Yu-peng Ren, Yue Qiu, Jenny Zheng, Gai-ling Li, Chuan-pu Hu, Tian-yan Zhou, Wei Lu, Liang Li. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C. Acta Pharmacologica Sinica 2018; 39(1): 140 doi: 10.1038/aps.2017.84
|
8 |
Satoshi Takakusagi, Ken Sato, Yuhei Suzuki, Yuichi Yamazaki, Takashi Kosone, Satoru Kakizaki, Motoyasu Kusano, Hitoshi Takagi. Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia. Internal Medicine 2018; 57(15): 2189 doi: 10.2169/internalmedicine.9624-17
|